<DOC>
	<DOCNO>NCT01870726</DOCNO>
	<brief_summary>The study assess safety dose combination INC280 buparlisib ( BKM120 ) , well anti-tumor activity combination , patient recurrent glioblastoma PTEN mutation , homozygous deletion PTEN PTEN negative IHC . In addition , anti-tumor activity INC280 single agent assess patient recurrent glioblastoma c-Met alteration .</brief_summary>
	<brief_title>Safety Efficacy INC280 Buparlisib ( BKM120 ) Patients With Recurrent Gliobastoma</brief_title>
	<detailed_description>This multi-center , open-label , phase Ib/II study . The aim phase Ib part estimate MTD and/or identify recommend phase II dose ( RP2D ) combination INC280 buparlisib , follow phase II part ass clinical efficacy INC280 single agent combination buparlisib ( BKM120 ) , assess safety combination . A maximum 10 patient ( combination arm ) approx . 5 patient ( single agent arm ) , receive bevacizumab treatment enter study , enrol phase II part . In addition , surgical arm start concurrently phase II part , determine PK/PD profile study drug combination patient undergoing tumor resection recurrent glioblastoma 7 10-days treatment .</detailed_description>
	<criteria>≥ 18 year age . Histologically confirm diagnosis glioblastoma ( initial tumor resection biopsy ) radiographic evidence recurrent tumor per RANO criterion . Phase Ib : Documented evidence PTEN mutation , homozygous deletion PTEN PTEN negative ( H Score &lt; 10 ) IHC confirm local central assessment . Phase II : Documented evidence cMet amplification ( GCN &gt; 5 ) ( fusion transcript mutant cMet may eligible discussion Novartis ) PTEN mutation , homozygous deletion PTEN PTEN negative ( H Score &lt; 10 ) central assessment . Must receive follow treatment glioblastoma : •Prior treatment radiotherapy temozolomide ; Note : A maximum two prior chemotherapy/antibody regimen ( include bevacizumab direct VEFG/VEGFR inhibitor ) recurrent disease permit . Representative archival tumor sample glioblastoma ( formalinfixed paraffine embed tissue ) must available . ECOG performance status ≤ 2 . Able swallow retain oral medication . Patients surgical arm : patient recurrent glioblastoma must eligible surgical resection deem site Investigator . Prior current treatment cMET inhibitor HGFtargeting therapy Prior treatment PI3K and/or mTOR inhibitor glioblastoma preexist neoplasm transform glioblastoma ( applicable combination treatment arm ) Received radiation ( include therapeutic radioisotope strontium 89 ) therapy ≤ 3 month prior first dose study treatment recover side effect therapy ( ≤ Grade 1 ) prior first dose study treatment , except alopecia . Receiving treatment medication know strong inhibitor inducer CYP3A , discontinue 7 day prior start treatment course study . Receiving treatment medication know CYP3A , CYP1A2 , CYP2C8 , CYP2C9 CYP2C19 substrates narrow therapeutic index , discontinue course study . Receiving treatment long act proton pump inhibitor , discontinue 3 day prior start INC280 treatment course study . Currently receive warfarin coumadinderived anticoagulant treatment , prophylaxis otherwise . Currently receive increase chronic treatment ( &gt; 5 day ) corticosteroid ( e.g . dexamethasone &gt; 4 mg/day corticosteroid equivalent dose ) another immunosuppressive agent . History acute chronic pancreatitis risk factor may increase risk pancreatitis . Active cardiac disease history cardiac dysfunction . Impairment gastrointestinal ( GI ) function GI disease might significantly alter absorption study drug Medically document history active major depressive episode , bipolar disorder ( I II ) , obsessivecompulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation ( e.g . risk harm self others ) , patient active severe personality disorder ( define accord DSM IV ) . Anxiety ≥ CTCAE grade 3 Any follow baseline laboratory value : Hemoglobin &lt; 9 g/dL Platelet count &lt; 75 x 109/L Absolute neutrophil count ( ANC ) &lt; 1.0 x 109/L INR &gt; 1.5 Serum lipase &gt; normal limit institution Asymptomatic serum amylase &gt; grade 2 Potassium , magnesium , calcium ( correct albumin ) &gt; normal limit institution Total bilirubin &gt; 1.5 x ULN Serum creatinine &gt; 1.5 x ULN creatinine clearance ≤ 45 mL/min Alanine aminotransferase ( AST ) aspartate aminotransferase ( ALT ) &gt; 3.0 x ULN ( &lt; 5.0 x ULN liver metastasis present ) Fasting plasma glucose &gt; 120mg/dL &gt; 6.7 mmol/L HbA1c &gt; 8 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>